The beneficial effect of metformin on β‐cell function in non‐obese Chinese subjects with newly diagnosed type 2 diabetes

摘要: Aim Studies with metformin suggest a favourable change in β-cell function over sulphonylureas the early course of obese type 2 diabetes mellitus (T2DM), but it remains unclear whether similar effect is observed non-obese individuals. Here we investigated effects or glipizide gastrointestinal therapeutics system extended-release formulation (GITS) on patients newly diagnosed T2DM. Methods A total 160 fasting glucose 7.0–13.0 mmol/L and body mass index <30 kg/m2 from five centres China were randomized to GITS for 24 weeks. Early insulin secretion [the ratio area under curve (AUC) during 0–30 min (InsAUC30/GluAUC30)] sensitivity [Matsuda (ISIM)] assessed standard meal tolerance test before after therapy. Plasma glucagon-like peptide-1(GLP-1) glucagon levels also measured. Results Metformin improved InsAUC30/GluAUC30 significantly (from 8.1 ± 0.6 pmol/mmol 10.7 ± 0.7 pmol/mmol, p < 0.05), comparable results GITS. In metformin-treated lean (body index < 25 kg/m2) subgroup, increase ISIM was not significant, improvement great magnitude. Increased GLP-1 responses decreased level treatment. Correlation analysis showed that associated changes HbA1c (r = −0.374, p = 0.000), (r = 0.356, p = 0.001), ΔGLP-10–30 (r = 0.225, p = 0.02). Conclusions Metformin subjects T2DM, which partly independent these subjects. This study provides evidence-based data support use T2DM as first-line agent, can improve both function. Copyright © 2013 John Wiley & Sons, Ltd.